Highlights
Urolithin A (UA; Mitopure) administered orally for 4 months to middle‑aged, overweight, sedentary adults was safe and associated with: 1) significant improvements in lower‑limb (hamstring) strength (+12% with 500 mg, +9.8% with 1,000 mg versus placebo), 2) clinically meaningful increases in aerobic capacity and walking distance with the 1,000 mg dose (peak VO2 up ~10% within‑group; 6‑minute walk distance +33.4 m), and 3) muscle proteomic and biochemical signatures consistent with activation of Parkin‑mediated mitophagy and elevated mitochondrial OXPHOS proteins, together with reduced systemic CRP and selected inflammatory cytokines.
